CLINICAL RESPIRATORY JOURNAL, cilt.12, sa.4, ss.1628-1634, 2018 (SCI-Expanded)
BackgroundPulmonary thromboembolism (PTE) is a life-threatening disease. In this study, we aimed to evaluate long-term outcomes of the use of 50mg recombinant tissue-type plasminogen activator (rt-PA) in the management of PTE in terms of relapse, pulmonary hypertension (PH), mortality and hemorrhage and to compare with the use of 100mg rt-PA.